98%
921
2 minutes
20
CD146 involvement was recently described in skin fibrosis of systemic sclerosis through its regulation of the Wnt pathway. Because the interaction between Wnt and ROS signaling plays a major role in fibrosis, we hypothesized that in systemic sclerosis, CD146 may regulate Wnt/ROS crosstalk. Using a transcriptomic and western blot analysis performed on CD146 wild-type or knockout mouse embryonic fibroblasts, we showed a procanonical Wnt hallmark in the absence of CD146 that is reversed when CD146 expression is restored. We found an elevated ROS content in knockout cells and an increase in DNA oxidative damage in the skin sections of knockout mice compared with those of wild-type mice. We also showed that ROS increased CD146 and its noncanonical Wnt ligand, WNT5A, only in wild-type cells. In humans, fibroblasts from patients with systemic sclerosis presented higher ROS content and expressed CD146, whereas control fibroblasts did not. Moreover, CD146 and its ligand were upregulated by ROS in both human fibroblasts. The increase in bleomycin-induced WNT5A expression was abrogated when CD146 was silenced. We showed an interplay between Wnt and ROS signaling in systemic sclerosis, regulated by CD146, which promotes the noncanonical Wnt pathway and prevents ROS signaling, opening the way for innovative therapeutic strategies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jid.2022.03.038 | DOI Listing |
Mod Rheumatol
September 2025
Chugai Pharmaceutical Co., Ltd., 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo 103-8324, Japan.
ObjectivesThe 2023 EULAR guidelines for systemic sclerosis (SSc) newly recommend biologics (rituximab, tocilizumab), mycophenolate mofetil (MMF), and nintedanib in addition to cyclophosphamide for interstitial lung disease (ILD). This study investigated recent actual use of these drugs in Japan. MethodsWe analysed data from a Japanese hospital claims database (2020-2023), identifying patients with SSc disease codes (ICD-10 M34.
View Article and Find Full Text PDFArthritis Rheumatol
August 2025
Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Objective: To evaluate dynamic changes in autoantibody and proteomic profiles in treatment-naïve systemic sclerosis (SSc) patients and identify biomarkers and mechanisms associated with disease progression.
Methods: Serum samples from 30 baseline and 49 follow-up SSc patients, along with 38 controls, were analyzed. Autoantibody profiles were assessed using an autoantigen microarray targeting 120 autoantibodies, while proteomic analysis was conducted via liquid chromatography-mass spectrometry in data-independent acquisition mode.
Women Health
September 2025
Nezahat Keleşoğlu Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Necmettin Erbakan University, Konya, Turkey.
This study compared the pelvic floor dysfunction (PFD) symptoms, knowledge level and quality of life inwomen with systemic sclerosis (SSc) and healthy. The study included 30 SSc and 30 healthy women. The presence and severity of PFD symptoms were evaluated using the Pelvic Floor Distress Inventory-20 (PFDI-20) (Subscales: Pelvic Organ Prolapse Distress Inventory-6 (POPDI-6), Colorectal-Anal Distress Inventory-8 (CRADI-8), and Urinary Distress Inventory-6 (UDI-6)).
View Article and Find Full Text PDFExp Neurobiol
August 2025
Department of Anatomy, Jeju National University College of Medicine, Jeju 63243, Korea.
Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis (MS). The latter is a human organ-specific autoimmune disease of the central nervous system (CNS). EAE is characterized by systemic inflammation associated with increased blood levels of proinflammatory mediators that potentially trigger inflammation of both reproductive organs and the CNS.
View Article and Find Full Text PDFClin Exp Rheumatol
September 2025
Department of Rheumatology and Immunology, Sichuan Tianfu New Area People's Hospital, Chengdu, Sichuan, China.